Diabetes mellitus: Channeling care through cellular discovery

Current Neurovascular Research

Volumn 7, Issue 1, 2010, Pages 59-74

  Maiese, Kenneth ^a   Shang, Yan Chen ^a   Chong, Zhao Zhong ^a   Hou, Jinling ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Biomarkers; Diabetes; Erythropoietin; FoxO3a; Oxidative stress; Sirtuins; Wnt

Indexed keywords

ERYTHROPOIETIN; FORKHEAD TRANSCRIPTION FACTOR; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTEIN KINASE B; SIRTUIN; TRANSCRIPTION FACTOR FKHRL1; WNT PROTEIN;

AGING; APOPTOSIS; CELL CYCLE REGULATION; CELL ENERGY; CELL PROTECTION; CELL SURVIVAL; DIABETES MELLITUS; DROSOPHILA; ERYTHROPOIESIS; EXCITOTOXICITY; HUMAN; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAMMAL CELL; MENTAL DEVELOPMENT; METABOLIC SYNDROME X; MICROGLIA; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 77949750863     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720210790820217     Document Type: Review

References (409)

1. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007; 14(16): 1729-38.
2. Maiese K, Morhan SD, Chong ZZ. Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 2007; 4(1): 63-71.
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301(20): 2129-40.
4. Rebecchi KR, Wenke JL, Go EP, Desaire H. Label-free quantitation: a new glycoproteomics approach. J Am Soc Mass Spectrom 2009; 20(6): 1048-59.
5. Maiese K. Diabetic stress: new triumphs and challenges to maintain vascular longevity. Expert Rev Cardiovasc Ther 2008; 6(3): 281-4.
6. Daneman D. Type 1 diabetes. Lancet 2006; 367(9513): 847-58.
7. Dabelea D, Bell RA, D'Agostino RB, Jr., et al. Incidence of diabetes in youth in the United States. JAMA 2007; 297(24): 2716-24.
8. Development OfEC-oa. OECD Health Data 2009; www.ecosante.org/oecd.htm.
9. Hao J, Shen W, Tian C, et al. Mitochondrial nutrients improve immune dysfunction in the type 2 diabetic Goto-Kakizaki rats. J Cell Mol Med 2009; 13(4): 701-11.
10. Morley JE. Diabetes, sarcopenia, and frailty. Clin Geriatr Med 2008; 24(3): 455-69, vi.
11. McIntyre RS, Rasgon NL, Kemp DE, et al. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009; 9(1): 51-9.
12. Wu SY, Wang GF, Liu ZQ, et al. Effect of geniposide, a hypoglycemic glucoside, on hepatic regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Acta Pharmacol Sin 2009; 30(2): 202-8.
13. Guarnieri G, Zanetti M, Vinci P, Cattin MR, Barazzoni R. Insulin resistance in chronic uremia. J Ren Nutr 2009; 19(1): 20-4.
14. Aso Y, Suganuma R, Wakabayashi S, et al. Anemia is associated with an elevated serum level of high-molecular-weight adiponectin in patients with type 2 diabetes independently of renal dysfunction. Transl Res 2009; 154(4): 175-82.
15. Gossai D, Lau-Cam CA. The effects of taurine, taurine homologs and hypotaurine on cell and membrane antioxidative system alterations caused by type 2 diabetes in rat erythrocytes. Adv Exp Med Biol 2009; 643: 359-68.
16. Singh DK, Winocour P, Farrington K. Erythropoietic stress and anemia in diabetes mellitus. Nat Rev Endocrinol 2009; 5(4): 204-10.
17. Maiese K. Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus. Biomed Pharmacother 200; 62(4): 218-32.
18. Maiese K, Chong Z, Li F. Reducing oxidative stress and enhancing neurovascular longevity during diabetes mellitus. In: Neurovascular Medicine: pursuing cellular longevity for healthy aging Maiese, K, Ed, New York NY: Oxford University Press 2009; pp. 540-64, ISBN13: 978-0-19-532669-7, ISBN10: 0-19-532669-5.
19. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007; 298(7): 765-75.
20. Kuhad A, Bishnoi M, Tiwari V, Chopra K. Suppression of NF-kappabeta signaling pathway by tocotrienol can prevent diabetes associated cognitive deficits. Pharmacol Biochem Behav 2009; 92(2): 251-9.
21. Maiese K, Chong ZZ, Hou J, Shang YC. The vitamin nicotinamide: translating nutrition into clinical care. Molecules 2009; 14(9): 3446-85.
22. Maiese K, Chong ZZ, Hou J, Shang YC. New strategies for Alzheimer's disease and cognitive impairment. Oxid Med Cell Longev 2009; 2(5): 279-90.
23. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: Novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005; 75(3): 207-46.
24. Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 2005; 49(1): 1-21.
25. Maiese K, Holloway HH, Larson DM, Soncrant TT. Effect of acute and chronic arecoline treatment on cerebral metabolism and blood flow in the conscious rat. Brain Res 1994; 641(1): 65-75.
26. Kim HS, Lim JY, Sul D, et al. Neuroprotective effects of the new diterpene, CBNU06 against beta-amyloid-induced toxicity through the inhibition of NF-kappaB signaling pathway in PC12 cells. Eur J Pharmacol 2009; 622(1-3): 25-31.
27. Salminen A, Kaarniranta K. Siglec receptors and hiding plaques in Alzheimer's disease. J Mol Med 2009; 87(7): 697-701.
28. Chong ZZ, Li F, Maiese K. Attempted Cell cycle induction in postmitotic neurons occurs in early and late apoptotic programs through Rb, E2F1, and caspase 3. Curr Neurovasc Res 2006; 3(1): 25-39.
29. Lin SH, Chong ZZ, Maiese K. Cell cycle induction in post-mitotic neurons proceeds in concert with the initial phase of programmed cell death in rat. Neurosci Lett 2001; 310(2-3): 173-7.
30. Majd S, Zarifkar A, Rastegar K, Takhshid MA. Different fibrillar Abeta 1-42 concentrations induce adult hippocampal neurons to reenter various phases of the cell cycle. Brain Res 2008; 1218: 224-9.
31. Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2005; 2(5): 387-99.
32. Chong ZZ, Li F, Maiese K. Cellular demise and inflammatory microglial activation during beta-amyloid toxicity are governed by Wnt1 and canonical signaling pathways. Cell Signal 2007; 19(6): 1150-62.
33. Majd S, Rastegar K, Zarifkar A, Takhshid MA. Fibrillar β-amyloid (Aβ) (1-42) elevates extracellular Aβ in cultured hippocampal neurons of adult rats. Brain Res 2007; 1185: 321-7.
34. Shang YC, Chong ZZ, Hou J, Maiese K. The forkhead transcription factor FoxO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res 2009; 6(1): 20-31.
35. Bakshi P, Margenthaler E, Laporte V, Crawford F, Mullan M. Novel role of CXCR2 in regulation of gamma-secretase activity. ACS Chem Biol 2008; 3(12): 777-89.
36. Lu J, Wu DM, Zheng YL, et al. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav Immun 2009; 23(2): 193-203.
37. Bitner RS, Nikkel AL, Markosyan S, et al. Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3β and decreases tau phosphorylation in vivo. Brain Res 2009; 1265: 65-74.
38. Vaisid T, Barnoy S, Kosower NS. Calpastatin overexpression attenuates amyloid-β-peptide toxicity in differentiated PC12 cells. Neuroscience 2008; 156(4): 921-31.
39. Erol A. Unraveling the molecular mechanisms behind the metabolic basis of sporadic Alzheimer's disease. J Alzheimers Dis 2009; 17(2): 267-76.
40. Maiese K, Chong ZZ. Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 2003; 24(5): 228-32.
41. Schubert M, Gautam D, Surjo D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 2004; 101(9): 3100-5.
42. Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005; 60(4): 471-5.
43. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154(7): 635-41.
44. Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 2005; 7(1): 63-80.
45. Newsholme P, Haber EP, Hirabara SM, et al. Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity. J Physiol 2007; 583(Pt 1): 9-24.
46. Szabo C. Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol 2009; 156(5): 713-27.
47. Simone S, Gorin Y, Velagapudi C, Abboud HE, Habib SL. Mechanism of oxidative DNA damage in diabetes: tuberin inactivation and downregulation of DNA repair enzyme 8-oxo-7,8-dihydro-2′-deoxyguanosine-DNA glycosylase. Diabetes 2008; 57(10): 2626-36.
48. Gaddini L, Villa M, Matteucci A, et al. Early effects of high glucose in retinal tissue cultures Renin-Angiotensin system-dependent and -independent signaling. Neurobiol Dis 2009; 35(2): 278-85.
49. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol 2008; 4(4): 216-26.
50. Lin J, Zheng S, Chen A. Curcumin attenuates the effects of insulin on stimulating hepatic stellate cell activation by interrupting insulin signaling and attenuating oxidative stress. Lab Invest 2009; 89(12): 1397-409.
51. Barbosa NB, Oliveira C, Araldi D, et al. Acute diphenyl diselenide treatment reduces hyperglycemia but does not change delta-aminolevulinate dehydratase activity in alloxan-induced diabetes in rats. Biol Pharm Bull 2008; 31(12): 2200-4.
52. Memisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with type 2 diabetes mellitus. J Diabetes Comp 2004; 18(4): 193-7.
53. Chattopadhyay M, Walter C, Mata M, Fink DJ. Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain 2009; 132(Pt 4): 879-88.
54. Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res 2007; 4(3): 194-204.
55. Liu W, Liu P, Tao S, et al. Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Arch Biochem Biophys 2008; 475(2): 128-34.
56. Shang YC, Chong ZZ, Hou J, Maiese K. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res 2009; 6(4): 223-38.
57. Chen H, Li X, Epstein PN. MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes 2005; 54(5): 1437-46.
58. Lepore DA, Shinkel TA, Fisicaro N, et al. Enhanced expression of glutathione peroxidase protects islet beta cells from hypoxia-reoxygenation. Xenotransplantation 2004; 11(1): 53-9.
59. Ribeiro MC, Barbosa NB, de Almeida TM, et al. High-fat diet and hydrochlorothiazide increase oxidative stress in brain of rats. Cell Biochem Funct 2009; 27(7): 473-8.
60. Rachek LI, Thornley NP, Grishko VI, LeDoux SP, Wilson GL. Protection of INS-1 cells from free fatty acid-induced apoptosis by targeting hOGG1 to mitochondria. Diabetes 2006; 55(4): 1022-8.
61. Haber CA, Lam TK, Yu Z, et al. N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab 2003; 285(4): E744-53.
62. Maiese K. Marking the onset of oxidative stress: Biomarkers and novel strategies. Oxid Med Cell Longev 2009; 2(1): 1.
63. Maiese K, Hou J, Chong ZZ, Shang YC. Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. Sci World J 2009; 9: 1072-104.
64. Maiese K, Chong ZZ, Hou J, Shang YC. Erythropoietin and oxidative stress. Curr Neurovasc Res 2008; 5(2): 125-42.
65. Yano M, Hasegawa G, Ishii M, et al. Short-term exposure of high glucose concentration induces generation of reactive oxygen species in endothelial cells: implication for the oxidative stress associated with postprandial hyperglycemia. Redox Rep 2004; 9(2): 111-6.
66. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681-7.
67. De Felice FG, Velasco PT, Lambert MP, et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282(15): 11590-601.
68. Lin SH, Maiese K. The metabotropic glutamate receptor system protects against ischemic free radical programmed cell death in rat brain endothelial cells. J Cereb Blood Flow Metab 2001; 21(3): 262-75.
69. Chuang HH, Lin S. Oxidative challenges sensitize the capsaicin receptor by covalent cysteine modification. Proc Natl Acad Sci USA 2009; 106(47): 20097-102.
70. Nomoto M, Miyata M, Yin S, et al. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol Pharm Bull 2009; 32(2): 172-8.
71. Walsh KB, Toledo AH, Rivera-Chavez FA, Lopez-Neblina F, Toledo-Pereyra LH. Inflammatory mediators of liver ischemia-reperfusion injury. Exp Clin Transplant 2009; 7(2): 78-93.
72. Escobar J, Pereda J, Arduini A, et al. Cross-talk between oxidative stress and pro-inflammatory cytokines in acute pancreatitis: a key role for protein phosphatases. Curr Pharm Des 2009; 15(26): 3027-42.
73. Bouayed J, Rammal H, Soulimani R. Oxidative stress and anxiety: Relationship and cellular pathways. Oxid Med Cell Longev 2009; 2(2): 63-7.
74. Maiese K. High anxiety: recognizing stress as the stressor. Oxid Med Cell Longev 2009; 2(2): 61-2.
75. Campos-Esparza MR, Sanchez-Gomez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant polyphenols. Cell Calcium 2009; 45(4): 358-68.
76. Chong ZZ, Li F, Maiese K. Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and β-catenin during oxidative stress. Curr Neurovasc Res 2006; 3(2): 107-17.
77. He Z, Lu Q, Xu X, et al. DDPH ameliorated oxygen and glucose deprivation-induced injury in rat hippocampal neurons via interrupting Ca2+ overload and glutamate release. Eur J Pharmacol 2009; 603(1-3): 50-5.
78. Lehtinen MK, Tegelberg S, Schipper H, et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. J Neurosci 2009; 29(18): 5910-5.
79. Ye J, Han Y, Wang C, Yu W. Cytoprotective effect of polypeptide from Chlamys farreri on neuroblastoma (SH-SY5Y) cells following HO exposure involves scavenging ROS and inhibition JNK phosphorylation. J Neurochem 2009; 111(2): 441-51.
80. Anderson DW, Bradbury KA, Schneider JS. Broad neuroprotective profile of nicotinamide in different mouse models of MPTP-induced parkinsonism. Eur J Neurosci 2008; 28(3): 610-7.
81. Morissette M, Al Sweidi S, Callier S, Di Paolo T. Estrogen and SERM neuroprotection in animal models of Parkinson's disease. Mol Cell Endocrinol 2008; 290(1-2): 60-9.
82. Morissette M, Le Saux M, D'Astous M, et al. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J Steroid Biochem Mol Biol 2008; 108(3-5): 327-38.
83. Rodriguez-Blanco J, Martin V, Herrera F, et al. Intracellular signaling pathways involved in post-mitotic dopaminergic PC12 cell death induced by 6-hydroxydopamine. J Neurochem 2008; 107(1): 127-40.
84. Sales Santos I, da Rocha Tomé A, Saldanha G, et al. Oxidative stress in the hippocampus during experimental seizures can be ameliorated with the antioxidant ascorbic acid. Oxid Med Cell Longev 2009; 2(4): 23-30.
85. Maiese K, Chong ZZ, Shang YC, Hou J. Therapeutic promise and principles: Metabotropic glutamate receptors. Oxid Med Cell Longev 2008; 1(1): 1-14.
86. Probst-Hensch NM, Imboden M, Felber Dietrich D, et al. Glutathione S-transferase polymorphisms, passive smoking, obesity, and heart rate variability in nonsmokers. Environ Health Perspect 2008; 116(11): 1494-9.
87. Yemisci M, Gursoy-Ozdemir Y, Vural A, et al. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med 2009; 15(9): 1031-7.
88. Fatma N, Kubo E, Toris CB, et al. PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells. Free Radic Res 2009; 43(9): 783-95.
89. Gomes P, Simão S, Silva E, et al. Aging increases oxidative stress and renal expression of oxidant and antioxidant enzymes that are associated with an increased trend in systolic blood pressure. Oxid Med Cell Longev 2009; 2(3): 19-26.
90. Pedersen MO, Jensen R, Pedersen DS, et al. Metallothionein-I+II in neuroprotection. BioFactors (Oxford, England) 2009; 35(4): 315-25.
91. Astiz M, de Alaniz MJ, Marra CA. Effect of pesticides on cell survival in liver and brain rat tissues. Ecotoxicol Environ Saf 2009; 72(7): 2025-32.
92. Slotkin TA, Seidler FJ. Protein kinase C is a target for diverse developmental neurotoxicants: transcriptional responses to chlorpyrifos, diazinon, dieldrin and divalent nickel in PC12 cells. Brain Res 2009; 1263: 23-32.
93. Hamden K, Carreau S, Jamoussi K, et al. 1α,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan-induced diabetes in rats. J Nutr Sci Vitaminol (Tokyo) 2009; 55(3): 215-22.
94. Regulska M, Leskiewicz M, Budziszewska B, et al. Inhibitory effects of 1,25-dihydroxyvitamin D(3) and its low-calcemic analogues on staurosporine-induced apoptosis. Pharmacol Rep 2007; 59(4): 393-401.
95. Li F, Chong ZZ, Maiese K. Cell life versus cell longevity: the mysteries surrounding the NAD(+) precursor nicotinamide. Curr Med Chem 2006; 13(8): 883-95.
96. Li J, Wang H, Rosenberg PA. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. J Neurosci Res 2009; 87(9): 1997-2005.
97. Ozsoy N, Candoken E, Akev N. Implications for degenerative disorders: Antioxidative activity, total phenols, flavonoids, ascorbic acid, β-carotene, α-tocopherol in Aloe vera. Oxid Med Cell Longev 2009; 2(2): 99-106.
98. Then SM, Mazlan M, Mat Top G, Wan Ngah WZ. Is vitamin E toxic to neuron cells? Cell Mol Neurobiol 2009; 29(4): 485-96.
99. El-Mir MY, Detaille D, G RV, et al. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 2008; 34(1): 77-87.
100. Kui L, Weiwei Z, Ling L, et al. Ghrelin inhibits apoptosis induced by high glucose and sodium palmitate in adult rat cardiomyocytes through the PI3K-Akt signaling pathway. Regul Pept 2009; 155(1-3): 62-9.
101. Head BP, Patel HH, Niesman IR, et al. Inhibition of p75 neurotrophin receptor attenuates isoflurane-mediated neuronal apoptosis in the neonatal central nervous system. Anesthesiology 2009; 110(4): 813-25.
102. Han Z, Xiao MJ, Shao B, et al. Attenuation of ischemia-induced rat brain injury by 2-(-2-benzofuranyl)-2-imidazoline, a high selectivity ligand for imidazoline I(2) receptors. Neurol Res 2009; 31(4): 390-5.
103. Maiese K. From the bench to the bedside: the molecular management of cerebral ischemia. Clin Neuropharm 1998; 21(1): 1-7.
104. Maiese K, Pek L, Berger SB, Reis DJ. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J Cereb Blood Flow Metab 1992; 12(1): 53-63.
105. Nakka VP, Gusain A, Mehta SL, Raghubir R. Molecular mechanisms of apoptosis in cerebral ischemia: multiple neuroprotective opportunities. Mol Neurobiol 2008; 37(1): 7-38.
106. Cardoso L, Herman BC, Verborgt O, et al. Osteocyte apoptosis controls activation of intracortical resorption in response to bone fatigue. J Bone Miner Res 2009; 24(4): 597-605.
107. Arboleda G, Morales LC, Benitez B, Arboleda H. Regulation of ceramide-induced neuronal death: cell metabolism meets neurodegeneration. Brain Res Rev 2009; 59(2): 333-46.
108. Maiese K, Vincent AM. Critical temporal modulation of neuronal programmed cell injury. Cell Mol Neurobiol 2000; 20(3): 383-400.
109. Zhong J, Zheng W, Huang L, et al. PrP106-126 amide causes the semi-penetrated poration in the supported lipid bilayers. Biochim Biophys Acta 2007; 1768(6): 1420-9.
110. Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline provides protection against β-amyloid(25-35)-induced alterations of the somatostatin signaling pathway in the rat temporal cortex. Neuroscience 2008; 154(4): 1458-66.
111. Burgos-Ramos E, Puebla-Jimenez L, Arilla-Ferreiro E. Minocycline prevents Aβ(25-35)-induced reduction of somatostatin and neprilysin content in rat temporal cortex. Life Sci 2009; 84(7-8): 205-10.
112. Casoli T, Di Stefano G, Giorgetti B, et al. Release of β-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann NY Acad Sci 2007; 1096: 170-8.
113. Kelley BJ, Knopman DS. Alternative medicine and Alzheimer disease. Neurologist 2008; 14(5): 299-306.
114. Liang WS, Dunckley T, Beach TG, et al. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genom 2008; 33(2): 240-56.
115. Verdaguer E, Susana Gde A, Clemens A, Pallas M, Camins A. Implication of the transcription factor E2F-1 in the modulation of neuronal apoptosis. Biomed Pharmacother 2007; 61(7): 390-9.
116. Sommer C. Neuronal plasticity after ischemic preconditioning and TIA-like preconditioning ischemic periods. Acta Neuropathol 2009; 117(5): 511-23.
117. Braga M, Sinha Hikim AP, Datta S, et al. Involvement of oxidative stress and caspase 2-mediated intrinsic pathway signaling in age-related increase in muscle cell apoptosis in mice. Apoptosis 2008; 13(6): 822-32.
118. Maiese K, Chong ZZ, Kang J. Transformation into treatment: novel therapeutics that begin within the cell. In: Maiese K, Ed. Neuronal and vascular plasticity: elucidating basic cellular mechanisms for future therapeutic discovery. Norwell, MA: Kluwer Academic Publishers 2003; pp. 1-26.
119. Gross J, Machulik A, Amarjargal N, et al. Expression of apoptosis-related genes in the organ of Corti, modiolus and stria vascularis of newborn rats. Brain Res 2007; 1162: 56-68.
120. Maiese K, Ahmad I, TenBroeke M, Gallant J. Metabotropic glutamate receptor subtypes independently modulate neuronal intracellular calcium. J Neurosci Res 1999; 55: 472-85.
121. Maiese K, Vincent AM. Membrane asymmetry and DNA degradation: functionally distinct determinants of neuronal programmed cell death. J Neurosci Res 2000; 59(4): 568-80.
122. Chong ZZ, Kang JQ, Maiese K. Metabotropic glutamate receptors promote neuronal and vascular plasticity through novel intracellular pathways. Histol Histopathol 2003; 18(1): 173-89.
123. Dombroski D, Balasubramanian K, Schroit AJ. Phosphatidylserine expression on cell surfaces promotes antibody- dependent aggregation and thrombosis in β2-glycoprotein I-immune mice. J Autoimmun 2000; 14(3): 221-9.
124. Jessel R, Haertel S, Socaciu C, Tykhonova S, Diehl HA. Kinetics of apoptotic markers in exogeneously induced apoptosis of EL4 cells. J Cell Mol Med 2002; 6(1): 82-92.
125. Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003; 64(3): 557-69.
126. Kang JQ, Chong ZZ, Maiese K. Akt1 protects against inflammatory microglial activation through maintenance of membrane asymmetry and modulation of cysteine protease activity. J Neurosci Res 2003; 74(1): 37-51.
127. Mari C, Karabiyikoglu M, Goris ML, et al. Detection of focal hypoxic-ischemic injury and neuronal stress in a rodent model of unilateral MCA occlusion/reperfusion using radiolabeled annexin V. Eur J Nucl Med Mol Imaging 2004; 31(5): 733-9.
128. Maiese K. The dynamics of cellular injury: transformation into neuronal and vascular protection. Histol Histopathol 2001; 16(2): 633-44.
129. Vincent AM, Maiese K. Direct temporal analysis of apoptosis induction in living adherent neurons. J Histochem Cytochem 1999; 47(5): 661-72.
130. Chong ZZ, Lin SH, Kang JQ, Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 2003; 71(5): 659-69.
131. Chong ZZ, Lin SH, Kang JQ, Maiese K. The tyrosine phosphatase SHP2 modulates MAP kinase p38 and caspase 1 and 3 to foster neuronal survival. Cell Mol Neurobiol 2003; 23(4-5): 561-78.
132. Maiese K, Boccone L. Neuroprotection by peptide growth factors against anoxia and nitric oxide toxicity requires modulation of protein kinase C. J Cereb Blood Flow Metab 1995; 15(3): 440-9.
133. Maiese K, Boniece IR, Skurat K, Wagner JA. Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. J Neurosci Res 1993; 36(1): 77-87.
134. Maiese K, TenBroeke M, Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997; 68(2): 710-4.
135. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J. Thrombin-triggered platelet apoptosis. J Thromb Haemost 2006; 4(12): 2656-63.
136. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009; 228(1): 149-69.
137. Maiese K, Chong ZZ, Shang YC, Hou J. A "FOXO" in sight: targeting Foxo proteins from conception to cancer. Med Res Rev 2009; 29(3): 395-418.
138. Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3β and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007; 19(2): 263-72.
139. Dello Russo C, Lisi L, Tringali G, Navarra P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol 2009; 78(9): 1242-51.
140. Lee SJ, Cho KS, Koh JY. Oxidative injury triggers autophagy in astrocytes: the role of endogenous zinc. Glia 2009; 57(12): 1351-61.
141. Martin I, Andres CR, Vedrine S, et al. Effect of the oligodendrocyte myelin glycoprotein (OMgp) on the expansion and neuronal differentiation of rat neural stem cells. Brain Res 2009; 1284: 22-30.
142. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol 2009; 9(7): 465-79.
143. Williams R, Dhillon NK, Hegde ST, et al. Proinflammatory cytokines and HIV-1 synergistically enhance CXCL10 expression in human astrocytes. Glia 2009; 57(7): 734-43.
144. Zhao L, Ma W, Fariss RN, Wong WT. Retinal vascular repair and neovascularization are not dependent on CX3CR1 signaling in a model of ischemic retinopathy. Exp Eye Res 2009; 88(6): 1004-13.
145. Dringen R. Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 2005; 7(9-10): 1223-33.
146. Maiese K, Chong ZZ. Insights into oxidative stress and potential novel therapeutic targets for Alzheimer disease. Restor Neurol Neurosci 2004; 22(2): 87-104.
147. Sankarapandi S, Zweier JL, Mukherjee G, Quinn MT, Huso DL. Measurement and characterization of superoxide generation in microglial cells: evidence for an NADPH oxidase-dependent pathway. Arch Biochem Biophys 1998; 353(2): 312-21.
148. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008; 28(10): 1707-21.
149. Wu Y, Peng H, Cui M, et al. CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem 2009; 109(4): 1157-67.
150. Mallat M, Marin-Teva JL, Cheret C. Phagocytosis in the developing CNS: more than clearing the corpses. Curr Opin Neurobiol 2005; 15(1): 101-7.
151. Chong ZZ, Kang J, Li F, Maiese K. mGluRI targets microglial activation and selectively prevents neuronal cell engulfment through akt and caspase dependent pathways. Curr Neurovasc Res 2005; 2(3): 197-211.
152. Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3β, β-catenin, and nuclear factor-kappaB. Curr Neurovasc Res 2006; 3(3): 187-201.
153. Li F, Chong ZZ, Maiese K. Winding through the WNT pathway during cellular development and demise. Histol Histopathol 2006; 21(1): 103-24.
154. He XL, Wang YH, Gao M, et al. Baicalein protects rat brain mitochondria against chronic cerebral hypoperfusion-induced oxidative damage. Brain Res 2009; 1249: 212-21.
155. Maiese K, Chong ZZ, Shang YC, Hou J. Rogue proliferation versus restorative protection: where do we draw the line for Wnt and forkhead signaling? Expert opinion on therapeutic targets 2008; 12(7): 905-16.
156. Plecita-Hlavata L, Lessard M, Santorova J, Bewersdorf J, Jezek P. Mitochondrial oxidative phosphorylation and energetic status are reflected by morphology of mitochondrial network in INS-1E and HEP-G2 cells viewed by 4Pi microscopy. Biochim Biophys Acta 2008; 1777(7-8): 834-46.
157. Di Lisa F, Menabo R, Canton M, Barile M, Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001; 276(4): 2571-5.
158. Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, Cytochrome c, and Caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 2003; 23(3): 320-30.
159. Lin SH, Vincent A, Shaw T, Maynard KI, Maiese K. Prevention of nitric oxide-induced neuronal injury through the modulation of independent pathways of programmed cell death. J Cereb Blood Flow Metab 2000; 20(9): 1380-91.
160. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51(10): 2944-50.
161. Choo HJ, Kim JH, Kwon OB, et al. Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia 2006; 49(4): 784-91.
162. Rex A, Fink H. Pharmacokinetic aspects of reduced nicotinamide adenine dinucleotide (NADH) in rats. Front Biosci 2008; 13: 3735-41.
163. Li F, Chong ZZ, Maiese K. Navigating novel mechanisms of cellular plasticity with the NAD+ precursor and nutrient nicotinamide. Front Biosci 2004; 9: 2500-20.
164. Jackson TM, Rawling JM, Roebuck BD, Kirkland JB. Large supplements of nicotinic acid and nicotinamide increase tissue NAD+ and poly(ADP-ribose) levels but do not affect diethylnitrosamine-induced altered hepatic foci in Fischer-344 rats. J Nutr 1995; 125(6): 1455-61.
165. Wojcik M, Seidle HF, Bieganowski P, Brenner C. Glutamine-dependent NAD+ synthetase. How a two-domain, three-substrate enzyme avoids waste. J Biol Chem 2006; 281(44): 33395-402.
166. Khan JA, Forouhar F, Tao X, Tong L. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert opinion on therapeutic targets 2007; 11(5): 695-705.
167. Khan JA, Xiang S, Tong L. Crystal structure of human nicotinamide riboside kinase. Structure 2007; 15(8): 1005-13.
168. Magni G, Amici A, Emanuelli M, et al. Enzymology of NAD+ homeostasis in man. Cell Mol Life Sci 2004; 61(1): 19-34.
169. Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol 2003; 15(2): 241-6.
170. Hageman GJ, Stierum RH. Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res 2001; 475(1-2): 45-56.
171. Idelson M, Alper R, Obolensky A, et al. Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell 2009; 5(4): 396-408.
172. Aoyagi S, Archer TK. Nicotinamide uncouples hormone-dependent chromatin remodeling from transcription complex assembly. Mol Cell Biol 2008; 28(1): 30-9.
173. Bruno V, Battaglia G, Copani A, et al. Activation of class II or III metabotropic glutamate receptors protects cultured cortical neurons against excitotoxic degeneration. Eur J Neurosci 1995; 7(9): 1906-13.
174. Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur J Neurosci 2006; 24(11): 3174-82.
175. Chong ZZ, Lin SH, Maiese K. The NAD+ precursor nicotinamide governs neuronal survival during oxidative stress through protein kinase B coupled to FOXO3a and mitochondrial membrane potential. J Cereb Blood Flow Metab 2004; 24(7): 728-43.
176. Feng Y, Paul IA, LeBlanc MH. Nicotinamide reduces hypoxic ischemic brain injury in the newborn rat. Brain Res Bull 2006; 69(2): 117-22.
177. Lin SH, Chong ZZ, Maiese K. Nicotinamide: a nutritional supplement that provides protection against neuronal and vascular injury. J Med Food 200; 4(1): 27-38.
178. Slomka M, Zieminska E, Salinska E, Lazarewicz JW. Neuroprotective effects of nicotinamide and 1-methylnicotinamide in acute excitotoxicity in vitro. Folia Neuropathol 2008; 46(1): 69-80.
179. Slomka M, Zieminska E, Lazarewicz J. Nicotinamide and 1-methylnicotinamide reduce homocysteine neurotoxicity in primary cultures of rat cerebellar granule cells. Acta Neurobiol Exp (Wars) 2008; 68(1): 1-9.
180. Ieraci A, Herrera DG. Nicotinamide protects against ethanol-induced apoptotic neurodegeneration in the developing mouse brain. PLoS Med 2006; 3(4): e101.
181. Shen CC, Huang HM, Ou HC, et al. Protective effect of nicotinamide on neuronal cells under oxygen and glucose deprivation and hypoxia/ reoxygenation. J Biomed Sci 2004; 11(4): 472-81.
182. Sonee M, Martens JR, Evers MR, Mukherjee SK. The effect of tertiary butylhydroperoxide and nicotinamide on human cortical neurons. Neurotoxicology 2003; 24(3): 443-8.
183. Kiuchi K, Kondo M, Ueno S, et al. Functional rescue of N-methyl-N-nitrosourea-induced retinopathy by nicotinamide in Sprague-Dawley rats. Curr Eye Res 2003; 26(6): 355-62.
184. Kiuchi K, Yoshizawa K, Shikata N, Matsumura M, Tsubura A. Nicotinamide prevents N-methyl-N-nitrosourea-induced photoreceptor cell apoptosis in Sprague-Dawley rats and C57BL mice. Exp Eye Res 2002; 74(3): 383-92.
185. Reber F, Geffarth R, Kasper M, et al. Graded sensitiveness of the various retinal neuron populations on the glyoxal-mediated formation of advanced glycation end products and ways of protection. Graefes Arch Clin Exp Ophthalmol 2003; 241(3): 213-25.
186. Hoane MR, Gilbert DR, Holland MA, Pierce JL. Nicotinamide reduces acute cortical neuronal death and edema in the traumatically injured brain. Neurosci Lett 2006; 408(1): 35-9.
187. Hoane MR, Kaplan SA, Ellis AL. The effects of nicotinamide on apoptosis and blood-brain barrier breakdown following traumatic brain injury. Brain Res 2006; 1125(1): 185-93.
188. Hoane MR, Pierce JL, Holland MA, Anderson GD. Nicotinamide treatment induces behavioral recovery when administered up to 4 hours following cortical contusion injury in the rat. Neuroscience 2008; 154(3): 861-8.
189. Hoane MR, Pierce JL, Kaufman NA, Beare JE. Variation in chronic nicotinamide treatment after traumatic brain injury can alter components of functional recovery independent of histological damage. Oxid Med Cell Longev 2008; 1(1): 45-52.
190. Holland MA, Tan AA, Smith DC, Hoane MR. Nicotinamide treatment provides acute neuroprotection and GFAP regulation following fluid percussion injury. J Neurotrauma 2008; 25(2): 140-52.
191. Wallis RA, Panizzon KL, Girard JM. Traumatic neuroprotection with inhibitors of nitric oxide and ADP- ribosylation. Brain Res 1996; 710(1-2): 169-77.
192. Wang J, Zhai Q, Chen Y, et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 2005; 170(3): 349-55.
193. Yang J, Klaidman L, Chang M, et al. Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model. Pharmacol Biochem Behav 2002; 73(4): 901-10.
194. Gupta S, Kaul CL, Sharma SS. Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats. Neurol Res 2004; 26(1): 103-7.
195. Sakakibara Y, Mitha AP, Ayoub IA, Ogilvy CS, Maynard KI. Delayed treatment with nicotinamide (vitamin B3) reduces the infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fischer 344 rats. Brain Res 2002; 931(1): 68-73.
196. Macleod MR, O'Collins T, Howells DW, Donnan GA. Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 2004; 35(5): 1203-8.
197. Brewer KL, Hardin JS. Neuroprotective effects of nicotinamide after experimental spinal cord injury. Acad Emerg Med 2004; 11(2): 125-30.
198. Isbir CS, Ak K, Kurtkaya O, et al. Ischemic preconditioning and nicotinamide in spinal cord protection in an experimental model of transient aortic occlusion. Eur J Cardiothorac Surg 2003; 23(6): 1028-33.
199. Williams A, Ramsden D. Nicotinamide: a double edged sword. Parkinsonism Relat Disord 2005; 11(7): 413-20.
200. Williams AC, Cartwright LS, Ramsden DB. Parkinson's disease: the first common neurological disease due to auto-intoxication? QJM 2005; 98(3): 215-26.
201. Chong ZZ, Lin SH, Maiese K. Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res 2002; 39(2): 131-47.
202. Slominska EM, Yuen A, Osman L, et al. Cytoprotective effects of nicotinamide derivatives in endothelial cells. Nucleosides Nucleotides Nucleic Acids 2008; 27(6): 863-6.
203. Beck H, Plate KH. Angiogenesis after cerebral ischemia. Acta Neuropathol 2009; 117(5): 481-96.
204. Giulumian AD, Meszaros LG, Fuchs LC. Endothelin-1-induced contraction of mesenteric small arteries is mediated by ryanodine receptor Ca2+ channels and cyclic ADP-ribose. J Cardiovasc Pharmacol 2000; 36(6): 758-63.
205. Pietrzak L, Mogielnicki A, Buczko W. Nicotinamide and its metabolite N-methylnicotinamide increase skin vascular permeability in rats. Clin Exp Dermatol 2009; 34(3): 380-4.
206. Oumouna-Benachour K, Hans CP, Suzuki Y, et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation 2007; 115(18): 2442-50.
207. Giammona LM, Fuhrken PG, Papoutsakis ET, Miller WM. Nicotinamide (vitamin B3) increases the polyploidisation and proplatelet formation of cultured primary human megakaryocytes. Br J Haematol 2006; 135(4): 554-66.
208. Chong ZZ, Lin SH, Li F, Maiese K. The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through Akt, Bad, PARP, and mitochondrial associated "anti-apoptotic" pathways. Curr Neurovasc Res 2005; 2(4): 271-85.
209. Maiese K, Lin S, Chong ZZ. Elucidating neuronal and vascular injury through the cytoprotective agent nicotinamide. Curr Med Chem-Immune Endocr Metab Agents 2001; 1(3): 257-67.
210. Mateuszuk L, Khomich TI, Slominska E, et al. Activation of nicotinamide N-methyltrasferase and increased formation of 1-methylnicotinamide (MNA) in atherosclerosis. Pharmacol Rep 2009; 61(1): 76-85.
211. Vincent AM, Maiese K. Nitric oxide induction of neuronal endonuclease activity in programmed cell death. Exp Cell Res 1999; 246(2): 290-300.
212. Vincent AM, TenBroeke M, Maiese K. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp Neurol 1999; 155(1): 79-94.
213. Vincent AM, TenBroeke M, Maiese K. Neuronal intracellular pH directly mediates nitric oxide-induced programmed cell death. J Neurobiol 1999; 40(2): 171-84.
214. Young GS, Jacobson EL, Kirkland JB. Water maze performance in young male Long-Evans rats is inversely affected by dietary intakes of niacin and may be linked to levels of the NAD+ metabolite cADPR. J Nutr 2007; 137(4): 1050-7.
215. Reddy S, Bibby NJ, Wu D, et al. A combined casein-free- nicotinamide diet prevents diabetes in the NOD mouse with minimum insulitis. Diabetes Res Clin Pract 1995; 29(2): 83-92.
216. Hu Y, Wang Y, Wang L, et al. Effects of nicotinamide on prevention and treatment of streptozotocin-induced diabetes mellitus in rats. Chin Med J (Engl) 1996; 109(11): 819-22.
217. Stevens MJ, Li F, Drel VR, et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 2007; 320(1): 458-64.
218. Cresto JC, Fabiano de Bruno LE, Cao GF, et al. The association of acetyl-l-carnitine and nicotinamide remits the experimental diabetes in mice by multiple low-dose streptozotocin. Pancreas 2006; 33(4): 403-11.
219. Chlopicki S, Swies J, Mogielnicki A, et al. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts antithrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br J Pharmacol 2007; 152(2): 230-9.
220. Hara N, Yamada K, Shibata T, et al. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem 2007; 282(34): 24574-82.
221. Lee HI, Cho HJ, Han JA, et al. Transient downregulation of protein O-N-acetylglucosaminylation by treatment of high-dose nicotinamide in human cells. Exp Mol Med 2008; 40(2): 246-53.
222. Tam D, Tam M, Maynard KI. Nicotinamide modulates energy utilization and improves functional recovery from ischemia in the in vitro rabbit retina. Ann NY Acad Sci 2005; 1053: 258-68.
223. Olmos PR, Hodgson MI, Maiz A, et al. Nicotinamide protected first-phase insulin response (FPIR) and prevented clinical disease in first-degree relatives of type-1 diabetics. Diabetes Res Clin Pract 2006; 71(3): 320-33.
224. Crino A, Schiaffini R, Ciampalini P, et al. A two year observational study of nicotinamide and intensive insulin therapy in patients with recent onset type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005; 18(8): 749-54.
225. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20(7): 1378-84.
226. Zhou SS, Li D, Sun WP, et al. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 2009; 15(45): 5674-84.
227. Liu HK, Green BD, Flatt PR, McClenaghan NH, McCluskey JT. Effects of long-term exposure to nicotinamide and sodium butyrate on growth, viability, and the function of clonal insulin secreting cells. Endocr Res 2004; 30(1): 61-8.
228. Reddy S, Salari-Lak N, Sandler S. Long-term effects of nicotinamide-induced inhibition of poly(adenosine diphosphate-ribose) polymerase activity in rat pancreatic islets exposed to interleukin-1 β. Endocrinology 1995; 136(5): 1907-12.
229. Gaudineau C, Auclair K. Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem Biophys Res Commun 2004; 317(3): 950-6.
230. Halestrap AP, Woodfield KY, Connern CP. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase. J Biol Chem 1997; 272(6): 3346-54.
231. La Piana G, Marzulli D, Consalvo MI, Lofrumento NE. Cytochrome c-induced cytosolic nicotinamide adenine dinucleotide oxidation, mitochondrial permeability transition, and apoptosis. Arch Biochem Biophys 2003; 410(2): 201-11.
232. Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004; 25(11): 577-83.
233. Maiese K, Chong Z, Hou J, Shang Y. The "O" class: crafting clinical care with FoxO transcription factors. Adv Exp Med Biol 2009; 665: 242-60.
234. Maiese K, Chong ZZ, Shang YC, Hou J. FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond) 2009; 116(3): 191-203.
235. Maiese K, Hou J, Chong ZZ, Shang YC. A fork in the path: Developing therapeutic inroads with FoxO proteins. Oxid Med Cell Longev 2009; 2(3): 119-26.
236. Porcu M, Chiarugi A. The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension. Trends Pharmacol Sci 2005; 26(2): 94-103.
237. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 2007; 26(37): 5489-504.
238. Maiese K, Chong ZZ, Shang YC. OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008; 14(5): 219-27.
239. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG. Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 2008; 65(24): 4000-18.
240. Zschoernig B, Mahlknecht U. SIRTUIN 1: regulating the regulator. Biochem Biophys Res Commun 2008; 376(2): 251-5.
241. Tang BL, Chua CE. SIRT1 and neuronal diseases. Mol Aspects Med 2008; 29(3): 187-200.
242. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89(4): 1121-32.
243. Canto C, Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab 2009; 20(7): 325-31.
244. Balan V, Miller GS, Kaplun L, et al. Life span extension and neuronal cell protection by Drosophila nicotinamidase. J Biol Chem 2008; 283(41): 27810-9.
245. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res 2008; 86(2): 403-10.
246. Chong ZZ, Maiese K. Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways. Curr Neurovasc Res 2008; 5(3): 159-70.
247. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol 2009; 29(5): 1363-74.
248. Zillikens MC, van Meurs JB, Rivadeneira F, et al. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes 2009; 58(12): 2828-34.
249. Lee HI, Jang SY, Kang HT, Hwang ES. p53-, SIRT1-, and PARP-1-independent downregulation of p21WAF1 expression in nicotinamide-treated cells. Biochem Biophys Res Commun 2008; 368(2): 298-304.
250. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 2003; 278(51): 50985-98.
251. Bitterman KJ, Anderson RM, Cohen HY, Latorre-Esteves M, Sinclair DA. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem 2002; 277(47): 45099-107.
252. Cai AL, Zipfel GJ, Sheline CT. Zinc neurotoxicity is dependent on intracellular NAD levels and the sirtuin pathway. Eur J Neurosci 2006; 24(8): 2169-76.
253. Kruszewski M, Szumiel I. Sirtuins (histone deacetylases III) in the cellular response to DNA damage - facts and hypotheses. DNA Repair (Amst) 2005; 4(11): 1306-13.
254. Maiese K, Chong ZZ, Li F, Shang YC. Erythropoietin: Elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008; 85: 194-213.
255. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293(1): 90-5.
256. Girgenti MJ, Hunsberger J, Duman CH, et al. Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 2009; 66(3): 267-74.
257. Ma R, Xiong N, Huang C, et al. Erythropoietin protects PC12 cells from β-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology 2009; 56(6-7): 1027-34.
258. Sun ZK, Yang HQ, Pan J, et al. Protective effects of erythropoietin on tau phosphorylation induced by β-amyloid. J Neurosci Res 2008; 86(13): 3018-27.
259. McLeod M, Hong M, Mukhida K, et al. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease. Eur J Neurosci 2006; 24(2): 361-70.
260. Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003; 138(6): 1107-18.
261. Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 2007; 150(7): 839-50.
262. Cuzzocrea S, Mazzon E, di Paola R, et al. Erythropoietin reduces the degree of arthritis caused by type II collagen in the mouse. Arthritis Rheum 2005; 52(3): 940-50.
263. Thorne M, Moore CS, Robertson GS. Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice. J Neuroimmunol 2009; 211(1-2): 92-100.
264. Sanchez PE, Fares RP, Risso JJ, et al. Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons. Proc Natl Acad Sci USA 2009; 106(24): 9848-53.
265. Sanchez PE, Navarro FP, Fares RP, et al. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span. J Comp Neurol 2009; 514(4): 403-14.
266. Slotkin TA, Seidler FJ, Fumagalli F. Targeting of neurotrophic factors, their receptors, and signaling pathways in the developmental neurotoxicity of organophosphates in vivo and in vitro. Brain Res Bull 2008; 76(4): 424-38.
267. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev 2008; 59(1): 22-33.
268. Andreotti F, Agati L, Conti E, et al. Update on phase II studies of erythropoietin in acute myocardial infarction. Rationale and design of exogenous erythropoietin in acute myocardial infarction: new outlook and dose association study (EPAMINONDAS). J Thromb Thrombolysis 2009; 28(4): 489-95.
269. Brunner S, Winogradow J, Huber BC, et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J 2009; 23(2): 351-61.
270. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106(23): 2973-9.
271. Incagnoli P, Ramond A, Joyeux-Faure M, et al. Erythropoietin improved initial resuscitation and increased survival after cardiac arrest in rats. Resuscitation 2009; 80(6): 696-700.
272. Li CL, Jiang J, Fan YQ, et al. Knockout of the tumor necrosis factor a receptor 1 gene can up-regulate erythropoietin receptor during myocardial ischemia-reperfusion injury in mice. Chin Med J (Engl) 2009; 122(5): 566-70.
273. Schlecht-Bauer D, Antier D, Machet MC, Hyvelin JM. Short- and long-term cardioprotective effect of darbepoetin-α: role of Bcl-2 family proteins. J Cardiovasc Pharmacol 2009 Jul 10.
274. Smith K, Semple D, Bhandari S, Seymour AM. Cellular basis of uraemic cardiomyopathy: a role for erythropoietin? Eur J Heart Fail 2009; 11(8): 732-8.
275. Timmer SA, De Boer K, Knaapen P, Gotte MJ, Van Rossum AC. The potential role of erythropoietin in chronic heart failure: from the correction of anemia to improved perfusion and reduced apoptosis? J Card Fail 2009; 15(4): 353-61.
276. Uitterdijk A, Groenendijk BC, van Der Giessen WJ. Stem cell therapy for chronic heart failure. Hellenic J Cardiol 2009; 50(2): 127-32.
277. Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J 2009; 18(3): 314-23.
278. Yoo JY, Won YJ, Lee JH, et al. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures. J Neurosci Res 2009; 87(1): 150-63.
279. Okutan O, Turkoglu OF, Gok HB, Beskonakli E. Neuroprotective effect of erythropoietin after experimental cold injury-induced vasogenic brain edema in rats. Surg Neurol 2008 Nov; 70(5): 498-502.
280. Karaca M, Odabasoglu F, Kumtepe Y, et al. Protective effects of erythropoietin on ischemia/reperfusion injury of rat ovary. Eur J Obstet Gynecol Reprod Biol 2009; 144(2): 157-62.
281. Harder Y, Amon M, Schramm R, et al. Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent manner. Surgery 2009; 145(4): 372-83.
282. Rotter R, Menshykova M, Winkler T, et al. Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue. J Orthop Res 2008 Dec; 26(12): 1618-26.
283. Zhu L, Wang HD, Yu XG, et al. Erythropoietin prevents zinc accumulation and neuronal death after traumatic brain injury in rat hippocampus: in vitro and in vivo studies. Brain Res 2009 Sep 15; 1289: 96-105.
284. Aoshiba K, Onizawa S, Tsuji T, Nagai A. Therapeutic effects of erythropoietin in murine models of endotoxin shock. Crit Care Med 2009 Mar; 37(3): 889-98.
285. Contaldo C, Elsherbiny A, Lindenblatt N, et al. Erythropoietin enhances oxygenation in critically perfused tissue through modulation of nitric oxide synthase. Shock 2009; 31(6): 599-606.
286. Simon F, Calzia E, Radermacher P, Schelzig H. Beneficial effects of erythropoietin in models of shock and organ failure-nothing is simple and easy. Shock 2009; 31(2): 220-1.
287. Casals-Pascual C, Idro R, Picot S, Roberts DJ, Newton CR. Can erythropoietin be used to prevent brain damage in cerebral malaria? Trends Parasitol 2009; 25(1): 30-6.
288. Mihaila RG, Rezi EC, Boitan M, et al. Erythropoietin and the proinflammatory cytokines in chronic C hepatitis. Hepatogastroenterology 2009; 56(91-92): 751-5.
289. Picot S, Bienvenu AL, Konate S, et al. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. Malar J 2009; 8: 169.
290. MacRedmond R, Singhera GK, Dorscheid DR. Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury. Eur Respir J 2009 ; 33(6): 1403-14.
291. Tascilar O, Cakmak GK, Tekin IO, et al. Protective effects of erythropoietin against acute lung injury in a rat model of acute necrotizing pancreatitis. World J Gastroenterol 2007; 13(46): 6172-82.
292. Wu H, Dong G, Liu H, et al. Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor-alpha and matrix metalloproteinase-9 expression. Eur J Pharmacol 2009; 602(2-3): 406-12.
293. Chang YK, Choi DE, Na KR, et al. Erythropoietin attenuates renal injury in an experimental model of rat unilateral ureteral obstruction via anti-inflammatory and anti-apoptotic effects. J Urol 2009; 181(3): 1434-43.
294. Chen HH, Tarng DC, Lee KF, Wu CY, Chen YC. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease. J Nephrol 2008; 21(4): 543-9.
295. Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009; 30(3): 253-60.
296. Luo YH, Li ZD, Liu LX, Dong GH. Pretreatment with erythropoietin reduces hepatic ischemia-reperfusion injury. Hepatobiliary Pancreat Dis Int 2009; 8(3): 294-9.
297. Schmeding M, Hunold G, Ariyakhagorn V, et al. Erythropoietin reduces ischemia-reperfusion injury after liver transplantation in rats. Transpl Int 2009; 22(7): 738-46.
298. Ucan BH, Irkorucu O, Cakmak GK, et al. Erythropoietin: a possible cytoprotective cytokine in acute necrotizing pancreatitis. J Hepatobiliary Pancreat Surg 2009; 16(4): 530-7.
299. Lagreze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol 2009; 93(12): 1667-71.
300. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: a candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007; 16(6): 567-71.
301. Wang ZY, Shen LJ, Tu L, et al. Erythropoietin protects retinal pigment epithelial cells from oxidative damage. Free Radic Biol Med 2009; 46(8): 1032-41.
302. Zhong YS, Liu XH, Cheng Y, Min YJ. Erythropoietin with retrobulbar administration protects retinal ganglion cells from acute elevated intraocular pressure in rats. J Ocul Pharmacol Ther 2008; 24(5): 453-9.
303. Toba H, Sawai N, Morishita M, et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur J Pharmacol 2009; 612(1-3): 106-14.
304. Mikati MA, Hokayem JA, Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at p10. Epilepsia 2007; 48(1): 175-81.
305. Moon C, Krawczyk M, Paik D, et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006; 316(3): 999-1005.
306. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007; 19(3): 634-45.
307. Di Giacomo V, Sancilio S, Caravatta L, et al. Regulation of CREB activation by P38 mitogen activated protein kinase during human primary erythroblast differentiation. Int J Immunopathol Pharmacol 2009; 22(3): 679-88.
308. Koh SH, Noh MY, Cho GW, Kim KS, Kim SH. Erythropoietin increases the motility of human bone marrow-multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev 2009; 18(3): 411-21.
309. Tilling L, Chowienczyk P, Clapp B. Progenitors in motion: mechanisms of mobilization of endothelial progenitor cells. Br J Clin Pharmacol 2009; 68(4): 484-92.
310. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141(1): 14-31.
311. Schumann C, Triantafilou K, Krueger S, et al. Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm 2006; 2006(5): 18061.
312. Li F, Chong ZZ, Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 2004; 13(6): 265-89.
313. Maiese K, Chong ZZ, Shang YC. Raves and risks for erythropoietin. Cytokine Growth Factor Rev 2008; 19(2): 145-55.
314. Mojiminiyi OA, Abdella NA, Zaki MY, et al. Prevalence and associations of low plasma erythropoietin in patients with Type 2 diabetes mellitus. Diabet Med 2006; 23(8): 839-44.
315. Symeonidis A, Kouraklis-Symeonidis A, Psiroyiannis A, et al. Inappropriately low erythropoietin response for the degree of anemia in patients with noninsulin-dependent diabetes mellitus. Ann Hematol 2006; 85(2): 79-85.
316. Thomas MC, Cooper ME, Tsalamandris C, MacIsaac R, Jerums G. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005 28; 165(4): 466-9.
317. Teramo K, Kari MA, Eronen M, Markkanen H, Hiilesmaa V. High amniotic fluid erythropoietin levels are associated with an increased frequency of fetal and neonatal morbidity in type 1 diabetic pregnancies. Diabetologia 2004; 47(10): 1695-703.
318. Teramo KA, Widness JA. Increased fetal plasma and amniotic fluid erythropoietin concentrations: markers of intrauterine hypoxia. Neonatology 2009; 95(2): 105-16.
319. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26(4): 296-306.
320. Bierer R, Peceny MC, Hartenberger CH, Ohls RK. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006; 118(3): e635-40.
321. Pillai A, Dhandapani KM, Pillai BA, Terry AV, Jr., Mahadik SP. Erythropoietin prevents haloperidol treatment-induced neuronal apoptosis through regulation of BDNF. Neuropsychopharmacology 2008; 33(8): 1942-51.
322. Kaindl AM, Sifringer M, Koppelstaetter A, et al. Erythropoietin protects the developing brain from hyperoxia-induced cell death and proteome changes. Ann Neurol 2008; 64(5): 523-34.
323. Yis U, Kurul SH, Kumral A, et al. Effect of erythropoietin on oxygen-induced brain injury in the newborn rat. Neurosci Lett 2008; 448(3): 245-9.
324. He Z, Huang L, Wu Y, et al. DDPH: improving cognitive deficits beyond its α 1-adrenoceptor antagonism in chronic cerebral hypoperfused rats. Eur J Pharmacol 2008; 588(2-3): 178-88.
325. Berkingali N, Warnecke A, Gomes P, et al. Neurite outgrowth on cultured spiral ganglion neurons induced by erythropoietin. Hear Res 2008; 243(1-2): 121-6.
326. Shah RC, Wilson RS, Tang Y, et al. Relation of hemoglobin to level of cognitive function in older persons. Neuroepidemiology 2009; 32(1): 40-6.
327. Mason-Garcia M, Beckman BS, Brookins JW, et al. Development of a new radioimmunoassay for erythropoietin using recombinant erythropoietin. Kidney Int 1990; 38(5): 969-75.
328. Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45(9): 1406-12.
329. Gayer CP, Chaturvedi LS, Wang S, et al. Strain-induced proliferation requires the phosphatidylinositol 3-kinase/AKT/glycogen synthase kinase pathway. J Biol Chem 2009; 284(4): 2001-11.
330. An J, Zhang C, Polavarapu R, Zhang X, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008; 112(7): 2787-94.
331. Slaets H, Dumont D, Vanderlocht J, et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 2008; 8(6): 1237-47.
332. Dreixler JC, Hemmert JW, Shenoy SK, et al. The role of Akt/protein kinase B subtypes in retinal ischemic preconditioning. Exp Eye Res 2009; 88(3): 512-21.
333. Anitha M, Gondha C, Sutliff R, et al. GDNF rescues hyperglycemia-induced diabetic enteric neuropathy through activation of the PI3K/Akt pathway. J Clin Invest 2006; 116(2): 344-56.
334. Burgos-Ramos E, Martos-Moreno GA, Lopez MG, et al. The N-terminal tripeptide of insulin-like growth factor-I protects against beta-amyloid-induced somatostatin depletion by calcium and glycogen synthase kinase 3 β modulation. J Neurochem 2009; 109(2): 360-70.
335. Tamagno E, Guglielmotto M, Giliberto L, et al. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging 2009; 30(10): 1563-73.
336. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008; 324(1): 160-9.
337. Tajes M, Yeste-Velasco M, Zhu X, et al. Activation of Akt by lithium: pro-survival pathways in aging. Mech Ageing Dev 2009; 130(4): 253-61.
338. Chong ZZ, Kang JQ, Maiese K. Akt1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-x(L) and caspase 1, 3, and 9. Exp Cell Res 2004; 296(2): 196-207.
339. Fujiwara M, Izuishi K, Sano T, et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. J Exp Clin Cancer Res 2008; 27: 76.
340. Bahlmann FH, Song R, Boehm SM, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin α persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110(8): 1006-12.
341. Miki T, Miura T, Yano T, et al. Alteration in erythropoietin- induced cardioprotective signaling by postinfarct ventricular remodeling. J Pharmacol Exp Ther 2006; 317(1): 68-75.
342. Parsa CJ, Matsumoto A, Kim J, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112(7): 999-1007.
343. Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15(8): 2115-24.
344. Um M, Lodish HF. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. J Biol Chem 2006; 281(9): 5648-56.
345. Wu Y, Shang Y, Sun S, Liu R. Antioxidant effect of erythropoietin on 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cells. Eur J Pharmacol 2007; 564(1-3): 47-56.
346. Matsuzaki H, Tamatani M, Mitsuda N, et al. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 1999; 73(5): 2037-46.
347. Rytomaa M, Lehmann K, Downward J. Matrix detachment induces caspase-dependent cytochrome c release from mitochondria: inhibition by PKB/Akt but not Raf signalling. Oncogene 2000; 19(39): 4461-8.
348. Namikawa K, Honma M, Abe K, et al. Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J Neurosci 2000; 20(8): 2875-86.
349. Dzietko M, Felderhoff-Mueser U, Sifringer M, et al. Erythropoietin protects the developing brain against N-methyl-D-aspartate receptor antagonist neurotoxicity. Neurobiol Dis 2004; 15(2): 177-87.
350. Zhang Y, Park TS, Gidday JM. Hypoxic preconditioning protects human brain endothelium from ischemic apoptosis by Akt-dependent survivin activation. Am J Physiol Heart Circ Physiol 2007; 292(6): H2573-81.
351. Martin D, Salinas M, Lopez-Valdaliso R, et al. Effect of the Alzheimer amyloid fragment Aβ(25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem 2001; 78(5): 1000-8.
352. Henry MK, Lynch JT, Eapen AK, Quelle FW. DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. Blood 2001; 98(3): 834-41.
353. Maiese K, Chong ZZ, Li F. Driving cellular plasticity and survival through the signal transduction pathways of metabotropic glutamate receptors. Curr Neurovasc Res 2005; 2(5): 425-46.
354. Maiese K, Chong ZZ, Shang YC. "Sly as a FOXO": New paths with Forkhead signaling in the brain. Curr Neurovasc Res 2007; 4(4): 295-302.
355. Coffer PJ. When less is more: the PI3K pathway as a determinant of tumor response to dietary restriction. Cell Res 2009; 19(7): 797-9.
356. Jacobsen EA, Ananieva O, Brown ML, Chang Y. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene. J Immunol 2006; 176(11): 6831-8.
357. Maiese K, Chong ZZ, Shang YC, Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle 2008; 7(24): 3829-39.
358. Kaestner KH, Knochel W, Martinez DE. Unified nomenclature for the winged helix/forkhead transcription factors. Genes Dev 2000; 14(2): 142-6.
359. Lappas M, Lim R, Riley C, Rice GE, Permezel M. Localisation and expression of FoxO1 proteins in human gestational tissues. Placenta 2009; 30(3): 256-62.
360. Zheng WH, Kar S, Quirion R. FKHRL1 and its homologs are new targets of nerve growth factor Trk receptor signaling. J Neurochem 2002; 80(6): 1049-61.
361. Fei M, Lu M, Wang Y, et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol 2009; 26(2): 178-85.
362. Cariou A, Claessens YE, Pene F, et al. Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation 2008; 76(3): 397-404.
363. Bakker WJ, van Dijk TB, Parren-van Amelsvoort M, et al. Differential regulation of Foxo3a target genes in erythropoiesis. Mol Cell Biol 2007; 27(10): 3839-54.
364. Lei H, Quelle FW. FOXO transcription factors enforce cell cycle checkpoints and promote survival of hematopoietic cells after DNA damage. Mol Cancer Res 2009; 7(8): 1294-303.
365. Bethea CL, Reddy AP, Tokuyama Y, Henderson JA, Lima FB. Protective actions of ovarian hormones in the serotonin system of macaques. Front Neuroendocrinol 2009; 30(2): 212-38.
366. Chong ZZ, Kang JQ, Maiese K. Essential cellular regulatory elements of oxidative stress in early and late phases of apoptosis in the central nervous system. Antioxid Redox Signal 2004; 6(2): 277-87.
367. Fallarino F, Bianchi R, Orabona C, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200(8): 1051-62.
368. Nakae J, Cao Y, Oki M, et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure. Diabetes 2008; 57(3): 563-76.
369. Furuyama T, Yamashita H, Kitayama K, et al. Effects of aging and caloric restriction on the gene expression of Foxo1, 3, and 4 (FKHR, FKHRL1, and AFX) in the rat skeletal muscles. Microsc Res Tech 2002; 59(4): 331-4.
370. Puig O, Tjian R. Transcriptional feedback control of insulin receptor by dFOXO/FOXO1. Genes Dev 2005; 19(20): 2435-46.
371. Kim JR, Jung HS, Bae SW, et al. Polymorphisms in FOXO gene family and association analysis with BMI. Obesity (Silver Spring, MD) 2006; 14(2): 188-93.
372. Marchetti V, Menghini R, Rizza S, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes 2006; 55(8): 2231-7.
373. Kamagate A, Dong HH. Foxo1 integrates insulin signaling to VLDL production. Cell Cycle 2008; 7(20): 3162-70.
374. Ni YG, Wang N, Cao DJ, et al. FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci USA 2007; 104(51): 20517-22.
375. Kamei Y, Miura S, Suzuki M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem 2004; 279(39): 41114-23.
376. Liu CM, Yang Z, Liu CW, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther 2007; 14(12): 945-52.
377. Sandri M, Lin J, Handschin C, et al. PGC-1α protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophyspecific gene transcription. Proc Natl Acad Sci USA 2006; 103(44): 16260-5.
378. Maiese K, Li F, Chong ZZ, Shang YC. The Wnt signaling pathway: Aging gracefully as a protectionist? Pharmacol Ther 2008; 118(1): 58-81.
379. Speese SD, Budnik V. Wnts: up-and-coming at the synapse. Trends Neurosci 2007; 30(6): 268-75.
380. Espada J, Calvo MB, Diaz-Prado S, Medina V. Wnt signalling and cancer stem cells. Clin Transl Oncol 2009 Jul; 11(7): 411-27.
381. Jozwiak J, Kotulska K, Grajkowska W, et al. Upregulation of the WNT pathway in tuberous sclerosis-associated subependymal giant cell astrocytomas. Brain Dev 2007; 29(5): 273-80.
382. Jozwiak J, Wlodarski P. Hamartin and tuberin modulate gene transcription via β-catenin. J Neurooncol 2006; 79(3): 229-34.
383. Kikuchi A, Yamamoto H, Sato A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol 2009; 19(3): 119-29.
384. Lee JH, Lee EO, Kang JL, Chong YH. Concomitant degradation of beta-catenin and GSK-3 β potently contributes to glutamate-induced neurotoxicity in rat hippocampal slice cultures. J Neurochem 2008; 106(3): 1066-77.
385. Luo JM, Dai CF, Lin SY, Huang PQ. Asymmetric syntheses and Wnt signal inhibitory activity of melleumin A and four analogues of melleumins A and B. Chem Asian J 2009; 4(2): 328-35.
386. Mercado-Gomez O, Hernandez-Fonseca K, Villavicencio-Queijeiro A, et al. Inhibition of Wnt and PI3K signaling modulates GSK-3beta activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem Res 2008; 33(8): 1599-609.
387. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66(2): 236-53.
388. Sutton LP, Honardoust D, Mouyal J, Rajakumar N, Rushlow WJ. Activation of the canonical Wnt pathway by the antipsychotics haloperidol and clozapine involves dishevelled-3. J Neurochem 2007; 102(1): 153-69.
389. Vettor R, Milan G, Franzin C, et al. The origin of intermuscular adipose tissue and its pathophysiological implications. Am J Physiol Endocrinol Metab 2009 Sep 8.
390. Wang Z, Havasi A, Gall JM, et al. β-catenin promotes survival of renal epithelial cells by inhibiting Bax. J Am Soc Nephrol 2009; 20(9): 1919-28.
391. Wilusz M, Majka M. Role of the Wnt/β-catenin network in regulating hematopoiesis. Arch Immunol Ther Exp (Warsz) 2008; 56(4): 257-66.
392. Grant SF, Thorleifsson G, Reynisdottir I, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006 ; 38(3): 320-3.
393. Lehman DM, Hunt KJ, Leach RJ, et al. Haplotypes of transcription factor 7-like 2 (TCF7L2) gene and its upstream region are associated with type 2 diabetes and age of onset in mexican americans. Diabetes 2007; 56(2): 389-93.
394. Scott LJ, Bonnycastle LL, Willer CJ, et al. Association of transcription factor 7-like 2 (TCF7L2) variants with type 2 diabetes in a Finnish sample. Diabetes 2006; 55(9): 2649-53.
395. Guo YF, Xiong DH, Shen H, et al. Polymorphisms of the low-density lipoprotein receptor-related protein 5 (LRP5) gene are associated with obesity phenotypes in a large family-based association study. J Med Genet 2006; 43(10): 798-803.
396. Kanazawa A, Tsukada S, Sekine A, et al. Association of the gene encoding wingless-type mammary tumor virus integration-site family member 5B (WNT5B) with type 2 diabetes. Am J Hum Genet 2004; 75(5): 832-43.
397. Al-Aly Z, Shao JS, Lai CF, et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-α-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27(12): 2589-96.
398. Wright WS, Longo KA, Dolinsky VW, et al. Wnt10b Inhibits Obesity in ob/ob and Agouti Mice. Diabetes 2007; 56(2): 295-303.
399. Lin CL, Wang JY, Huang YT, et al. Wnt/β-catenin signaling modulates survival of high glucose-stressed mesangial cells. J Am Soc Nephrol 2006; 17(10): 2812-20.
400. Aslanidi G, Kroutov V, Philipsberg G, et al. Ectopic expression of Wnt10b decreases adiposity and improves glucose homeostasis in obese rats. Am J Physiol Endocrinol Metab 2007; 293(3): E726-36.
401. Mani A, Radhakrishnan J, Wang H, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007; 315(5816): 1278-82.
402. Lynch RL, Konicek BW, McNulty AM, et al. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005; 3(3): 163-9.
403. Hegde PS, Rusnak D, Bertiaux M, et al. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007; 6(5): 1629-40.
404. Hoekstra AV, Ward EC, Hardt JL, et al. Chemosensitization of endometrial cancer cells through AKT inhibition involves FOXO1. Gynecol Oncol 2008; 108(3): 609-18.
405. Maiese K, Li F, Chong ZZ. Erythropoietin and cancer. JAMA 2005; 293(15): 1858-9.
406. Barandon L, Couffinhal T, Ezan J, et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 2003; 108(18): 2282-9.
407. Barandon L, Dufourcq P, Costet P, et al. Involvement of FrzA/sFRP-1 and the Wnt/frizzled pathway in ischemic preconditioning. Circ Res 2005; 96(12): 1299-306.
408. Emami KH, Corey E. When prostate cancer meets bone: control by wnts. Cancer Lett 2007; 253(2): 170-9.
409. Sun J, Jin T. Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal 2008 ; 20(1): 219-29.